Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Tables)

v2.4.0.6
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2011
Income Taxes [Abstract]  
Schedule of income before income taxes
Income before income taxes consisted of the following (in millions):
Year Ended December 31,
2011

 
2010

 
2009

United States
$
3,010

 
$
7,224

1 
$
2,691

International
8,429

 
7,019

 
6,255

 
$
11,439

 
$
14,243

 
$
8,946

1 
The increase in 2010 was primarily attributable to a $4,978 million gain due to the remeasurement of our equity investment in CCE to fair value upon our acquisition of CCE's North American business. Refer to Note 2.
Schedule of income tax expense (benefit)
Income tax expense consisted of the following for the years ended December 31, 2011, 2010 and 2009 (in millions):
 
United States

 
State and Local

 
International

 
Total

2011
 
 
 
 
 
 
 
Current
$
286

 
$
66

 
$
1,425

 
$
1,777

Deferred
891

 
27

 
110

 
1,028

2010
 
 
 
 
 
 
 
Current
$
470

 
$
85

 
$
1,212

 
$
1,767

Deferred
599

 
2

 
16

 
617

2009
 
 
 
 
 
 
 
Current
$
509

 
$
79

 
$
1,099

 
$
1,687

Deferred
322

 
18

 
13

 
353

Reconciliation of the statutory U.S. federal tax rate and effective tax rates
A reconciliation of the statutory U.S. federal tax rate and our effective tax rate is as follows:
Year Ended December 31,
2011

 
2010

 
2009

 
Statutory U.S. federal tax rate
35.0
 %
 
35.0
 %
 
35.0
 %
 
State and local income taxes — net of federal benefit
0.9

 
0.6

 
0.7

 
Earnings in jurisdictions taxed at rates different from the statutory U.S. federal rate
(9.5
)
1,2.3 
(5.6
)
11 
(11.6
)
19 
Equity income or loss
(1.4
)
4 
(1.9
)
12 
(2.3
)
20 
CCE transaction

 
(12.5
)
13,14 

 
Sale of Norwegian and Swedish bottling operations

5 
0.4

15 

 
Other operating charges
0.3

6 
0.4

16 
0.6

21 
Other — net
(0.8
)
7,8,9,10 
0.3

17,18 
0.4

22,23 
Effective tax rate
24.5
 %
 
16.7
 %
 
22.8
 %
 
1 
Includes a tax benefit of $6 million related to amounts required to be recorded for changes to our uncertain tax positions, including interest and penalties, in various international jurisdictions.
2 
Includes a zero percent effective tax rate on charges due to the impairment of available-for-sale securities. Refer to Note 3 and Note 17.
3 
Includes a tax expense of $299 million (or a 0.7 percent impact on our effective tax rate) related to the net gain recognized as a result of the merger of Embotelladoras Arca, S.A.B. de C.V. ("Arca") and Grupo Continental S.A.B. ("Contal"), the gain recognized on the sale of our investment in Embonor and gains the Company recognized as a result of an equity method investee issuing additional shares of its own stock during the year at per share amounts greater than the carrying value of the Company's per share investment. These gains were partially offset by charges associated with certain of the Company's equity method investments in Japan. Refer to Note 17.
4 
Includes a tax benefit of $7 million (or a 0.1 percent impact on our effective tax rate) related to our proportionate share of asset impairments and restructuring charges recorded by certain of our equity method investees. Refer to Note 17.
5 
Includes a tax benefit of $2 million related to the finalization of working capital adjustments on the sale of our Norwegian and Swedish bottling operations. Refer to Note 2 and Note 17.
6 
Includes a tax benefit of $224 million (or a 0.3 percent impact on our effective tax rate) primarily related to the Company's productivity, integration and restructuring initiatives, transaction costs incurred in connection with the merger of Arca and Contal, costs associated with the earthquake and tsunami that devastated northern and eastern Japan and costs associated with the flooding in Thailand. Refer to Note 17.
7 
Includes a tax benefit of $8 million related to the amortization of favorable supply contracts acquired in connection with our acquisition of CCE's North American business.
8 
Includes a tax benefit of $3 million related to net charges we recognized on the repurchase and/or exchange of certain long-term debt assumed in connection with our acquisition of CCE's North American business as well as the early extinguishment of certain other long-term debt. Refer to Note 10.
9 
Includes a tax benefit of $14 million on charges due to the impairment of an investment in an entity accounted for under the equity method of accounting. Refer to Note 17.
10 
Includes a tax benefit of $2 million related to amounts required to be recorded for changes to our uncertain tax positions, including interest and penalties, in certain domestic jurisdictions.
11 
Includes tax expense of $265 million (or a 1.9 percent impact on our effective tax rate), primarily related to deferred tax expense on certain current year undistributed foreign earnings that are not considered indefinitely reinvested and amounts required to be recorded for changes to our uncertain tax positions, including interest and penalties.
12 
Includes a tax benefit of $9 million (or a 0.1 percent impact on our effective tax rate) related to charges recorded by our equity method investees. Refer to Note 17.
13 
Includes a tax benefit of $34 million (or a reduction of 12.5 percent on our effective tax rate) related to the remeasurement of our equity investment in CCE to fair value upon our acquisition of CCE's North American business. The tax benefit reflects the impact of reversing deferred tax liabilities associated with our equity investment in CCE prior to the acquisition. Refer to Note 2.
14 
Includes a tax benefit of $99 million related to charges associated with the write-off of preexisting relationships with CCE. Refer to Note 2.
15 
Includes a tax expense of $261 million (or a 0.4 percent impact on our effective tax rate) related to the sale of our Norwegian and Swedish bottling operations. Refer to Note 2.
16 
Includes a tax benefit of $223 million (or a 0.4 percent impact on our effective tax rate), primarily related to the Company's productivity, integration and restructuring initiatives, transaction costs and charitable contributions. Refer to Note 17.
17 
Includes a tax benefit of $114 million (or a 0.5 percent impact on our effective tax rate) related to charges associated with the repurchase of certain long-term debt and costs associated with the settlement of treasury rate locks issued in connection with the debt tender offer, the loss related to the remeasurement of our Venezuelan subsidiary's net assets, other-than-temporary impairment charges and a donation of preferred shares in one of our equity method investees. Refer to Note 17.
18 
Includes a tax expense of $31 million (or a 0.2 percent impact on our effective tax rate) related to amounts required to be recorded for changes to our uncertain tax positions, including interest and penalties, and other tax matters in certain domestic jurisdictions.
19 
Includes a tax benefit of $16 million (or a reduction of 0.2 percent on our effective tax rate) related to amounts required to be recorded for changes to our uncertain tax positions, including interest and penalties, in various international jurisdictions.
20 
Includes a tax benefit of $17 million (or a 0.1 percent impact on our effective tax rate) related to charges recorded by our equity method investees. Refer to Note 17.
21 
Includes a tax benefit of $16 million (or a 0.6 percent impact on our effective tax rate) related to restructuring charges and asset impairments. Refer to Note 17.
22 
Includes a zero percent effective rate (or a reduction of 0.2 percent on our effective tax rate) related to the sale of all or a portion of certain investments. Refer to Note 3.
23 
Includes a zero percent effective rate (or a 0.1 percent impact on our effective tax rate) related to an other-than-temporary impairment of a cost method investment. Refer to Note 17.
Reconciliation of the gross balance of unrecognized tax benefit
A reconciliation of the changes in the gross balance of unrecognized tax benefit amounts is as follows (in millions):
Year Ended December 31,
2011

 
2010

 
2009

Beginning balance of unrecognized tax benefits
$
387

 
$
354

 
$
369

Increases related to prior period tax positions
9

 
26

 
49

Decreases related to prior period tax positions
(19
)
 
(10
)
 
(28
)
Increases related to current period tax positions
6

 
33

 
16

Decreases related to current period tax positions
(1
)
 

 

Decreases related to settlements with taxing authorities
(5
)
 

 
(27
)
Reductions as a result of a lapse of the applicable statute of limitations
(46
)
 
(1
)
 
(73
)
Increase related to acquisition of CCE's North American business

 
6

 

Increases (decreases) from effects of foreign currency exchange rates
(11
)
 
(21
)
 
48

Ending balance of unrecognized tax benefits
$
320

 
$
387

 
$
354

Deferred tax assets and liabilities
The tax effects of temporary differences and carryforwards that give rise to deferred tax assets and liabilities consist of the following (in millions):
December 31,
2011

 
2010

 
Deferred tax assets:
 
 
 
 
Property, plant and equipment
$
224

 
$
49

 
Trademarks and other intangible assets
68

 
271

 
Equity method investments (including translation adjustment)
278

 
304

 
Net change in unrealized gain/loss
43

 
28

 
Other liabilities
1,257

 
1,257

 
Benefit plans
2,022

 
2,019

 
Net operating/capital loss carryforwards
818

 
911

 
Other
418

 
683

1 
Gross deferred tax assets
$
5,128

 
$
5,522

 
Valuation allowances
(859
)
 
(950
)
 
Total deferred tax assets2,3
$
4,269

 
$
4,572

 
Deferred tax liabilities:
 
 
 
 
Property, plant and equipment
$
(2,039
)
 
$
(2,227
)
 
Trademarks and other intangible assets
(4,201
)
 
(4,284
)
 
Equity method investments (including translation adjustment)
(816
)
 
(509
)
 
Net change in unrealized gain/loss
(129
)
 
(102
)
 
Other liabilities
(129
)
 
(5
)
 
Benefit plans
(445
)
 
(383
)
 
Other
(753
)
 
(765
)
 
Total deferred tax liabilities4
$
(8,512
)
 
$
(8,275
)
 
Net deferred tax liabilities
$
(4,243
)
 
$
(3,703
)
 
1 
Includes $183 million of tax credit carryforwards acquired in conjunction with our acquisition of CCE's North American business.
2 
Noncurrent deferred tax assets of $243 million and $98 million were included in the line item other assets in our consolidated balance sheets as of December 31, 2011 and 2010, respectively.
3 
Current deferred tax assets of $227 million and $478 million were included in the line item prepaid expenses and other assets in our consolidated balance sheets as of December 31, 2011 and 2010, respectively.
4 
Current deferred tax liabilities of $19 million and $18 million were included in the line item accounts payable and accrued expenses in our consolidated balance sheets as of December 31, 2011 and 2010, respectively.
Deferred tax asset valuation allowances
An analysis of our deferred tax asset valuation allowances is as follows (in millions):
Year Ended December 31,
2011

 
2010

 
2009

Balance at beginning of year
$
950

 
$
681

 
$
569

Increase due to our acquisition of CCE's North American business

 
291

 

Additions
138

 
115

 
178

Deductions
(229
)
 
(137
)
 
(66
)
Balance at end of year
$
859

 
$
950

 
$
681